Company: CRVO
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001437749-25-007829
Chunk: 119

Company: CervoMed Inc.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 119
---
Financial Statements

” of this Annual Report is incorporated herein by reference.

88

  ITEM 7A.      QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK  
 ───────────────────────────────────────────────────────────────────────────

As a “smaller reporting company” (as such term is defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information described in Item 305 of Regulation S-K and, accordingly, the information required by Item 7A of Form 10-K has been omitted from this Annual Report.

  ITEM 8.      FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA  
 ────────────────────────────────────────────────────────────

  Description                                                                                                                                              Page  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Report of Independent Registered Public Accounting Firm (PCAOB ID: 49)                                                                                     90  
  Consolidated Balance Sheets as of December 31, 2024 and 2023                                                                                               92  
  Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023                                                93  
  Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023        94  
  Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023                                                                       95  
  Notes to the Consolidated Financial Statements                                                                                                             96  

89

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of CervoMed Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of CervoMed Inc. and its subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States